277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy

Similar Items

• Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
  by: Charles Lu, et al.
  Published: (2024-10-01)
• Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
  by: Apar Pataer, MD, PhD, et al.
  Published: (2022-11-01)
• Abscopal downstaging of intermediate stage hepatocellular via combination cryoablation and immunotherapy with complete pathologic response
  by: Ana P. Lucas, MD, et al.
  Published: (2024-03-01)
• Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches
  by: Edwin R. Parra, et al.
  Published: (2018-06-01)
• 962 Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer
  by: Heather Lin, et al.
  Published: (2021-11-01)